News

BioM's articles and press releases about the Bavarian biotechnology sector


EU4Health 2025 calls for proposals: Advancing crisis preparedness through diagnostics and medical countermeasures

The European Health Emer­gency Pre­pared­ness and Re­sponse Author­ity (HERA) has launched two new EU4Health calls to strenght­en Europe’s…

Participation in International Conferences 2026: Explore Attractive Opportunities!

In 2026, BioM will once again sup­port par­ti­cip­a­tion in lead­ing in­ter­na­tion­al trade fairs - an ex­cel­lent op­por­tun­ity for…

EU-Japan Partnering in Osaka & BIO-Japan in Yokohama: BioM strengthens international networks at Japan’s leading industry events

From 6 to 10 Octo­ber 2025, BioM show­cased the Bav­ari­an bi­otech cluster in Japan - first at the EU-Japan Bi­otech & Pharma Part­ner­ing…

BIO-Europe 2025: BioMwith its own stand #B:68-12 at the German Pavilion!

BIO-Europe will take place from 3 - 6 Novem­ber 2025 in Vi­enna (Aus­tria). With over 5,500 par­ti­cipants from more than 60 coun­tries,…

New Max Planck Institute for Immunology planned in Würzburg

The Max Planck So­ci­ety and the Free State of Bav­aria have signed a memor­andum of un­der­stand­ing to strengthen bio­med­ic­al re­search…

m4 Award winner smartbax secures 4.7 million Euros in pre-Series A financing for novel antibiotic development

Mu­nich-based start-up smart­bax, a bi­otech com­pany de­vel­op­ing next-gen­er­a­tion an­ti­bi­ot­ics, has suc­cess­fully com­pleted a…

m4 Award winner Ulrike Protzer honored as Female Doctor of the Year

Prof. Dr. Ul­rike Protzer has been awar­ded the Ger­man Med­ic­al Award 2025 in the cat­egory “Fe­male Doc­tor of the Year.” The…

Record financing of 308 million euros for m4 Award winner Tubulis

The Mu­nich Bi­otech-Star­tup Tubulis, m4 Award win­ner of 2017, suc­cess­fully closes a EUR 308 mil­lion (USD 361 mil­lion) Ser­ies C to…

Apply now for GeneNovate Program 2026

You are a PhD stu­dent, Postdoc, or re­search­er in the life sci­ences, bi­otech, or medi­cine with an en­tre­pren­eur­i­al mind­set? Then…

Vivoryon Therapeutics N.V. raises EUR 5.1 million through private placement of new shares

Vivory­on Thera­peut­ics N.V., a clin­ic­al stage com­pany de­vel­op­ing small mo­lecule medi­cines for in­flam­mat­ory and fibrot­ic…